Trending...
- California: Governor Newsom announces appointments 12.4.24
- Ushio America to Exclusively Distribute Kooptech-Bio® LEGO® Washing Unit in North America
- IEI Technology USA Launches IMBAX-SP6: High-Performance ATX Motherboard for Edge AI Applications
SAN DIEGO ~ Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has appointed Martine Zimmermann, PharmD, to its Board of Directors as an independent director. Dr. Zimmermann brings 25 years of global experience in the pharmaceutical industry to Ligand's board.
John W. Kozarich, Ph.D., Chairman of Ligand, commented on the appointment: "We are very pleased to welcome Martine to our board of directors. She brings considerable expertise in development and regulatory affairs at a global level, having held senior roles in which she provided strategic regulatory direction on all phases of drug development and across multiple therapeutic areas. This skillset will be invaluable as we build our portfolio of partnered programs."
Dr. Zimmermann has extensive expertise in regulatory affairs at both small and large pharmaceutical organizations, having worked in the United States, Europe and Asia-Pacific. Throughout her career she has been involved in all phases of drug development and in several therapeutic areas, interacting with relevant regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
More on The Californer
Currently, Dr. Zimmermann is the Senior Vice President, Head of Regulatory Affairs and R&D Quality at Ipsen Biopharmaceuticals, a global biopharmaceutical company. Prior to Ipsen, she spent 13 years at Alexion Pharma International where she held several positions including Senior Vice President and Head of Global Regulatory Affairs. She is an active member of several life-sciences trade associations and was a member of the Board of Directors of Caelum Biosciences from 2019 until its acquisition by AstraZeneca in 2021; she has also been a board member of France-based Inventiva (Euronext Paris and Nasdaq: IVA) since 2021. Dr. Zimmermann received her Doctorate in Pharmacy (PharmD) with a specialty in immunology from the Louis Pasteur University, Strasbourg in France.
Ligand Pharmaceuticals Incorporated recently announced that it had appointed Martine Zimmermann, PharmD., to its Board of Directors as an independent director bringing 25 years worth of experience from the pharmaceutical industry with her to Ligand's board according to John W Kozarich Phd., Chairman for Ligand Pharmaceuticals Incorporated who commented "We are very pleased to welcome Martine to our board of directors" adding that "She brings considerable expertise in development and regulatory affairs at a global level"
More on The Californer
Dr Zimmermann has extensive experience working with relevant regulatory authorities such as The US Food & Drug Administration (FDA), The European Medicines Agency (EMA) & The Japanese Pharmaceuticals & Medical Devices Agency (PMDA). She is currently Senior Vice President & Head Of Regulatory Affairs & R&D Quality for Ipsen Biopharmaceuticals & was previously Senior Vice President & Head Of Global Regulatory Affairs for Alexion Pharma International for 13 years prior to joining Ipsen Biopharmaceuticals
Dr Zimmermann is also an active member for several life sciences trade associations & was part Of The Board Of Directors For Caelum Biosciences until it was acquired by AstraZeneca In 2021; She has also been part Of The Board Of Directors For France based Inventiva since 2021
Dr Zimmerman holds a Doctorate In Pharmacy With A Specialty In Immunology From Louis Pasteur University Strasbourg In France
John W. Kozarich, Ph.D., Chairman of Ligand, commented on the appointment: "We are very pleased to welcome Martine to our board of directors. She brings considerable expertise in development and regulatory affairs at a global level, having held senior roles in which she provided strategic regulatory direction on all phases of drug development and across multiple therapeutic areas. This skillset will be invaluable as we build our portfolio of partnered programs."
Dr. Zimmermann has extensive expertise in regulatory affairs at both small and large pharmaceutical organizations, having worked in the United States, Europe and Asia-Pacific. Throughout her career she has been involved in all phases of drug development and in several therapeutic areas, interacting with relevant regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
More on The Californer
- Lumaz Lighting Announces 2025 Holiday Season Sale: Up to 50% Off
- OpenID Foundation returns to Gartner IAM Summit to showcase interoperability in action
- Sir Rod Stewart reveals his model masterpiece in the UK
- $300 Billion in Estimated Annual Consumer Harm Linked to Fake Reviews, Transparency Company Research Report Reveals
- S.E,Gregg's Radio Interview On "Pursue Your Passion"
Currently, Dr. Zimmermann is the Senior Vice President, Head of Regulatory Affairs and R&D Quality at Ipsen Biopharmaceuticals, a global biopharmaceutical company. Prior to Ipsen, she spent 13 years at Alexion Pharma International where she held several positions including Senior Vice President and Head of Global Regulatory Affairs. She is an active member of several life-sciences trade associations and was a member of the Board of Directors of Caelum Biosciences from 2019 until its acquisition by AstraZeneca in 2021; she has also been a board member of France-based Inventiva (Euronext Paris and Nasdaq: IVA) since 2021. Dr. Zimmermann received her Doctorate in Pharmacy (PharmD) with a specialty in immunology from the Louis Pasteur University, Strasbourg in France.
Ligand Pharmaceuticals Incorporated recently announced that it had appointed Martine Zimmermann, PharmD., to its Board of Directors as an independent director bringing 25 years worth of experience from the pharmaceutical industry with her to Ligand's board according to John W Kozarich Phd., Chairman for Ligand Pharmaceuticals Incorporated who commented "We are very pleased to welcome Martine to our board of directors" adding that "She brings considerable expertise in development and regulatory affairs at a global level"
More on The Californer
- California: Governor Newsom appoints Adam Schiff to the U.S. Senate to complete remaining term ahead of full elected service
- Kxng Nosa Teams Up with Coaction Group: A Melodic Journey Toward Empowerment and Change
- California: Governor Newsom proclaims Pearl Harbor Remembrance Day 2024
- Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
- Breaking Music News: Taylor Swift Crowned Spotify's Global Top Artist of 2024!
Dr Zimmermann has extensive experience working with relevant regulatory authorities such as The US Food & Drug Administration (FDA), The European Medicines Agency (EMA) & The Japanese Pharmaceuticals & Medical Devices Agency (PMDA). She is currently Senior Vice President & Head Of Regulatory Affairs & R&D Quality for Ipsen Biopharmaceuticals & was previously Senior Vice President & Head Of Global Regulatory Affairs for Alexion Pharma International for 13 years prior to joining Ipsen Biopharmaceuticals
Dr Zimmermann is also an active member for several life sciences trade associations & was part Of The Board Of Directors For Caelum Biosciences until it was acquired by AstraZeneca In 2021; She has also been part Of The Board Of Directors For France based Inventiva since 2021
Dr Zimmerman holds a Doctorate In Pharmacy With A Specialty In Immunology From Louis Pasteur University Strasbourg In France
Filed Under: Business
0 Comments
Latest on The Californer
- New Preclinical Data Demonstrate Potential of Capsida's IV Gene Therapy for STXBP1-DEE to Correct all Disease Manifestations
- Pololikashvili runs for re-election as UN Tourism Secretary General for 2026-2029 term
- Long Beach Parks, Recreation and Marine to Offer Free Winter Fun Days Recreation Program for Youth Starting December 23
- Shape the Future of OpenSSL: Election Period Open Now!
- LIB Empowers Uzbekistan's Automotive Industry: A New Era of Quality Assurance
- TijaraIQ.com Launches as Iraq's Free Marketplace for Buying, Selling, and Creating Opportunities
- 'Man Of The Hour' and 'Sommet Dame' To Be Consolidated Into A New Platform
- Big News!! Best Sac Homes Group Partners with LPT Realty
- Long Beach Airport Wraps Up Centennial Celebration with Time Capsule, New Slogan and Pop-Up Pickleball Courts
- California: Governor Newsom announces appointments 12.5.24
- Governor Newsom and First Partner Siebel Newsom to induct the 18th class of the California Hall of Fame
- California: At Southern Border, Governor Newsom announces new Port-of-Entry construction to spur economic development and new efforts to bolster border security
- Juventix Regenerative Medical PRP Highlighted in University-Published Research Study
- IEI Technology USA Launches IMBAX-SP6: High-Performance ATX Motherboard for Edge AI Applications
- Governor Newsom issues emergency proclamation to support response to Northern California earthquake
- Dive into a haunting world where technology and terror collide
- Los Angeles Police Federal Credit Union Expands Into Additional Counties, Welcomes California and Federal Agencies
- Dale Sorensen Real Estate Names Donna Browning Vice President of Sales, Announcing Her Return to the Company
- Dr. Barrie Matthews of Big Sky Smile Center Speaks at the Full Arch Growth Conference, Inspiring Dentists Nationwide
- Agromin To Recycle Thousands Of Christmas Trees After The Holidays